Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy

被引:34
|
作者
Osipov, Arsen [1 ]
Nissen, Nicholas [2 ]
Rutgers, Joanne [3 ]
Dhall, Deepti [3 ]
Naziri, Jason [4 ]
Chopra, Shefali [3 ]
Li, Quanlin [1 ]
Hendifar, Andrew Eugene [1 ]
Tuli, Richard [4 ]
机构
[1] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA
[3] Cedars Sinai Med Ctr, Dept Pathol, Los Angeles, CA 90048 USA
[4] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90048 USA
关键词
RANDOMIZED CONTROLLED-TRIAL; DUCTAL ADENOCARCINOMA; CURATIVE RESECTION; PROGNOSTIC-FACTORS; R1; RESECTIONS; HEAD CANCER; CHEMOTHERAPY; METAANALYSIS; RECURRENCE; PANCREATICODUODENECTOMY;
D O I
10.1245/s10434-017-6076-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is debate regarding the definition and clinical significance of margin clearance in pancreatic ductal adenocarcinoma (PDA). A comprehensive archival analysis of surgical resection margins was performed to determine the effect on locoregional recurrence and survival, and the impact of adjuvant therapy in PDA. We identified 105 patients with resected PDA. Pancreatic, anterior, bile duct, and posterior surgical resection margins (PM; posterior surface, uncinate and vascular groove) were identified. Three pathologists reviewed all archival surgical specimens and recategorized each margin as tumor at ink/transected, < 0.5, 0.5-1, > 1-2, or > 2 mm from the inked surface. The impact of these and other clinical variables was assessed on local control, disease-free survival (DFS), and overall survival (OS). Among all margins, PM clearance up to 2 mm was prognostic of DFS (p = 0.01) and OS (p = 0.01). Dichotomizing the PM at 2 mm revealed it to be an independent predictor of local recurrence-free survival [hazard ratio HR] 0.20, 95% confidence interval [CI] 0.048-0.881, p = 0.033), DFS (HR 0.46, 95% CI 0.22-0.96, p = 0.03), and OS (HR 0.31, 95% CI 0.14-0.74, p = 0.008). A margin status of > 2 mm was also prognostic of OS in patients who received adjuvant chemotherapy (HR 0.31, 95% CI 0.11-0.89, p = 0.03), however this difference was mitigated in patients receiving adjuvant chemoradiotherapy (HR 0.40, 95% CI 0.10-1.58, p = 0.19). These data highlight the clinical significance of the PM and the lack of significance of other resection margins. Clearance in excess of 2 mm should be considered to improve long-term clinical outcomes. The use of adjuvant radiotherapy should be strongly considered in patients with PMs < 2 mm.
引用
收藏
页码:3674 / 3682
页数:9
相关论文
共 50 条
  • [41] Failure to Receive Adjuvant Therapy Following Resection for Pancreatic Cancer: Patterns and Implications
    Lewis, Russell S.
    Drebin, Jeffrey A.
    Callery, Mark P.
    Fraker, Douglas L.
    Kent, Tara S.
    Gates, Jenna
    Vollmer, Charles M.
    [J]. GASTROENTEROLOGY, 2012, 142 (05) : S1059 - S1060
  • [42] Outcomes and Long-term Survival with Adjuvant Chemoradiation Therapy for Duodenal Adenocarcinoma
    Tuli, R.
    Wang, J.
    Sugar, E.
    Wolfgang, C.
    Laheru, D.
    Cameron, J.
    Schulick, R.
    Poultsides, G.
    Herman, J. M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S285 - S285
  • [43] Margin Distance in Resected Pancreatic Cancer Independently Predicts Survival: Implications for Adjuvant Radiation Therapy
    Tuli, R.
    Osipov, A.
    Rutgers, K.
    Dhall, D.
    Naziri, J.
    Chopra, S.
    Li, Q.
    Hendifar, A. E.
    Nissen, N. N.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E214 - E214
  • [44] Effects of Neoadjuvant and Adjuvant Therapy for Rectal Cancer on Long Term Survival
    Mallipeddi, Mohan K.
    Speicher, Paul J.
    Ganapathi, Asvin M.
    Englum, Brian R.
    Migaly, John
    Mantyh, Christopher R.
    [J]. GASTROENTEROLOGY, 2014, 146 (05) : S342 - S342
  • [45] Adherence to long-term adjuvant hormonal therapy for breast cancer
    Gotay, Carolyn
    Dunn, Julia
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2011, 11 (06)
  • [47] LONG-TERM ADJUVANT TAMOXIFEN THERAPY FOR BREAST-CANCER
    JORDAN, VC
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1990, 15 (03) : 125 - 136
  • [48] Pancreatic Cancer and the Possibility of Long-term Survival A Glimmer of Hope?
    Ko, Andrew H.
    [J]. JAMA ONCOLOGY, 2016, 2 (03) : 380 - 381
  • [49] Long-term survival after surgical resection for pancreatic cancer
    Yoshizawa, K
    Nagai, H
    Kurihara, K
    Sata, N
    Kawai, T
    Saito, K
    [J]. HEPATO-GASTROENTEROLOGY, 2001, 48 (40) : 1153 - 1156
  • [50] Hospital Volume, Margin Status, and Long-Term Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma
    La Torre, Marco
    Nigri, Giuseppe
    Ferrari, Linda
    Cosenza, Giulia
    Ravaioli, Matteo
    Ramacciato, Giovanni
    [J]. AMERICAN SURGEON, 2012, 78 (02) : 225 - 229